Michael Scott Hite

US Patent:

7749537, Jul 6, 2010

Filed:

Oct 1, 2007

Appl. No.:

11/906303

Inventors:

Michael Hite - Seattle WA, US
Cathy Federici - Seattle WA, US
Alan Brunelle - Woodinville WA, US
Stephen Turner - Snoqualmie WA, US

Assignee:

SCOLR Pharma, Inc. - Bellevue WA

International Classification:

A61K 9/20
A61K 31/192

US Classification:

424468, 514568, 514770, 514781, 514570, 424465, 424464, 424480, 424482, 424481, 424462, 424461, 424458, 424457, 424456

Abstract:

A method of forming a tablet includes the steps of pre-blending an active pharmaceutical ingredient susceptible to tackiness and a blending additive with a first mixing effort to form a pre-blend mixture, wherein the first mixing effort and a second mixing effort, resulting from mixing at least one excipient with the pre-blend mixture, form a blend suitable for direct compression and compressing the blend to form the tablet. One way of achieving the first mixing effort is to pre-blend for an extended period of time. The method allows for directly compressing the blend without the need for a granulation step or roller compression. One such active pharmaceutical ingredient susceptible to tackiness is ibuprofen.

US Patent:

8007777, Aug 30, 2011

Filed:

Sep 30, 2002

Appl. No.:

10/261639

Inventors:

Tanya Borek - North Bend WA, US
Terri Butler - Kirkland WA, US
Catherine Federici - Seattle WA, US
Michael P. Hite - Seattle WA, US
Christopher London - Bellevue WA, US
Stephen J. Turner - Covington WA, US

Assignee:

Nutraceutix, Inc. - Redmond WA

International Classification:

A01N 63/00

US Classification:

424 931, 424 9345, 424 934, 424464, 424 9346, 424 935, 424 9351, 4352521, 4352529

Abstract:

The invention relates to a controlled release formulation for a probiotic. The formulation contains a hydrophilic agent, an electrolytic agent and a polysaccharide and is in the form of a monolithic tablet for oral delivery to the intestinal system. The probiotic can be lactic acid bacteria.

US Patent:

8540980, Sep 24, 2013

Filed:

Nov 27, 2012

Appl. No.:

13/686147

Inventors:

Stephen J. Turner - Snoqualmie WA, US
Tanya Borek - Bellevue WA, US
Catherine Federici - Seattle WA, US
Michael P. Hite - Normandy Park WA, US

Assignee:

TNTGamble, Inc. - Redmond WA

International Classification:

A01N 63/00

US Classification:

424 9345, 424 931, 424 934, 424464, 424 9346, 424 935, 424 9351, 4352521, 4352529

Abstract:

A controlled release delivery system composition and method applied to humans and animals, for oral, anal or vaginal administration of a biological component is disclosed. Preferably, a bacterium is delivered, and more preferably the bacterium is probiotic in nature, however, the biological component is not limited to the bacterium.

US Patent:

8609139, Dec 17, 2013

Filed:

Nov 5, 2008

Appl. No.:

12/741141

Inventors:

Eric Holmes - Bothell WA, US
Michael Hite - Seattle WA, US

Assignee:

Ala Wai Pharma, Inc. - Palo Alto CA

International Classification:

A61K 9/48

US Classification:

424463

Abstract:

A composition is described having improved oral permeability of polar agents such as neuraminidase inhibitors. The composition includes one or more polar agents and one or more permeability enhancers such that the composition increases the amount of the polar agent capable of being transported across a Caco-2 cell membrane by at least 150% relative to the amount capable of being transported across the Caco-2 Cell membrane in the absence of the permeability enhancer. Oral dosage forms including the composition, and methods of treating or preventing influenza infection are also provided.

US Patent:

20030175345, Sep 18, 2003

Filed:

Dec 6, 2002

Appl. No.:

10/313129

Inventors:

Michael Hite - Seattle WA, US
Stephen Turner - Covington WA, US
Catherine Federici - Seattle WA, US

International Classification:

A61K009/22
A61K031/7048
A61K031/353

US Classification:

424/468000, 514/027000, 514/456000

Abstract:

A controlled release delivery system composition and method for oral administration of an isoflavone is disclosed

US Patent:

20050152966, Jul 14, 2005

Filed:

Dec 13, 2004

Appl. No.:

11/010607

Inventors:

Tanya Borek - North Bend WA, US
Catherine Federici - Seattle WA, US
Michael Hite - Seattle WA, US
Christopher London - Bellevue WA, US
Stephen Turner - Covington WA, US

International Classification:

A61K045/00
A61K031/717
A61K031/716
A61K009/48
A61K009/20
A61K009/24

US Classification:

424451000, 424464000, 424093400, 514054000, 514057000, 514060000

Abstract:

A controlled release delivery system composition and method for oral administration of a biological component is disclosed. Preferably, a bacterium is delivered, and more preferably the bacterium is probiotic in nature.

US Patent:

20060068009, Mar 30, 2006

Filed:

Sep 29, 2005

Appl. No.:

11/238802

Inventors:

Michael Hite - Seattle WA, US
Cathy Federici - Seattle WA, US
Alan Brunelle - Woodinville WA, US
Stephen Turner - Snoqualmie WA, US

International Classification:

A61K 9/22

US Classification:

424468000

Abstract:

The present invention is a solid dosage form for oral administration of ibuprofen comprising a modified release formulation of ibuprofen which provides an immediate burst effect and thereafter a sustained release of sufficient ibuprofen to maintain blood levels at least 6.4 μg/ml over an extended period of at least 8 hours following administration of a single dose. The dosage form releases ibuprofen at a rate sufficient to initially deliver a effective amount of ibuprofen within about 2.0 hours following administration. The dosage form then subsequently delivers the remaining amount of ibuprofen at a relatively constant rate sufficient to maintain a level of ibuprofen over a predetermined delivery period of for at least 8 hours.

US Patent:

20070077297, Apr 5, 2007

Filed:

Dec 4, 2006

Appl. No.:

11/633322

Inventors:

Michael Hite - Seattle WA, US
Cathy Federici - Seattle WA, US
Alan Brunelle - Woodinville WA, US
Stephen Turner - Snoqualmie WA, US

International Classification:

A61K 31/192
A61K 9/20

US Classification:

424464000, 514570000

Abstract:

The present invention is a solid dosage form for oral administration of ibuprofen comprising a modified release formulation of ibuprofen which provides an immediate burst effect and thereafter a sustained release of sufficient ibuprofen to maintain blood levels at least 6.4 μg/ml over an extended period of at least 8 hours following administering of a single dose.